

Registered Office:

A-1106, Empire Business Hub, Nr. AUDA Water Tank, Science City Road, Sola, Ahmedabad-380060, Gujarat, India CIN No.: L24230GJ2012PLC071299

Date: 5th June, 2023

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001.

Dear Sir / Madam,

Sub: Announcement regarding opportunity of withdrawal for application subscribed by eligible equity shareholders / RE holders
Ref: Security Id: EARUM / Code: 542724

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to bring to the attention of the investors that there is misprint on page no 40 under the heading of Minimum Subscription in letter of offer dated April 19, 2023, the misprinting is in regards to the applicability of Minimum Subscription, which states that the requirement of minimum subscription in the Issue shall be applicable. Further, we wish to state that same is not applicable as we are satisfying both the conditions a. if object of the issue involves financing other than financing of capital expenditure for a project and b. our Promoter Mr. Bhumishth Patel, vide letter dated 24th January, 2023 has given intend to fully subscribe to their portion of rights entitlement not renounce their rights except to the extent of renunciation within the promoter group. Accordingly, in terms of Regulation 86(2) of the SEBI ICDR Regulations, is not applicable to the Issue.

Hence, due to this misprint of information all bidders, have the option to withdraw their Bids application from Monday, June 05, 2023, to Tuesday, June 06, 2023, till 5:00 P.M. The above-mentioned option to withdraw can be exercised by submitting a request for the same to the concerned Designated Intermediary or applying to the Registrar of Issue at rightsissue@bigshareonline.com or the Company at cs@earumpharma.com, who shall assist in such withdrawal of Bid cum Application Form. Investors should note the revised indicative timetable in respect of the Issue is set out below:

Event	Indicative Date
Finalisation of Basis of Allotment with the Designated Stock	On or before Thursday; June 15,
Exchange	2023
Initiation of refunds/ unblocking of funds from ASBA Account	On or before Friday; June 16, 2023
_ · ·	On or before Thursday; June 22, 2023
Commencement of trading of the Equity Shares on the Stock	On or before Monday; June 26,
Exchanges	2023

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the letter of offer dated April 19, 2023.

INVESTORS MAY PLEASE NOTE THE LETTER OF OFFER, THE APPLICATION FORMS, THE ABRIDGED LETTER OF OFFER AND GENERAL INFORMATION DOCUMENT SHALL BE READ IN CONJUNCTION WITH THIS CORRIGENDUM.

Phone: +91-79-48402525 | Email: info@earumpharma.com | Web.: www.earumpharma.com



Kindly take the same on your record and oblige us.

Thanking You.

For, Earum Pharmaceuticals Limited

Bhumishth Patel Director DIN: 02516641 Registered Office:

A-1106, Empire Business Hub, Nr. AUDA Water Tank, Science City Road, Sola, Ahmedabad-380060, Gujarat, India CIN No.: L24230GJ2012PLC071299

Phone: +91-79-48402525 | Email: info@earumpharma.com | Web.: www.earumpharma.com